CT-Bronchoscopy Workstation for Lung-Cancer Assessment

用于肺癌评估的 CT 支气管镜工作站

基本信息

项目摘要

This Phase-II SBIR project is in response to PAR-01-102, "Development of Novel Technologies for In Vivo Imaging." Expanding upon our Phase-I feasibility effort, we propose to construct and validate a complete workstation - the Virtual Navigator- for 3D MDCT-based planning and guidance of bronchoscopic biopsy. Lung cancer is the most common cause of cancer death in the western nations, with the current 5-year survival rate under 15%. Despite continued technological improvements, the lung-cancer mortality rate actually increased 11% between 1979 and 1997. The state-of-the-art procedure for diagnosing and staging lung cancer involves three-dimensional (3D) multi-detector computed-tomography (MDCT) scanning followed by bronchoscopic biopsy. Unfortunately, a high percentage of biopsy procedures are unsuccessful because of the: (1) lack of procedure-planning tools, (2) difficulty in seeing biopsy sites during bronchoscopy, and (3) wide range in physician skill level. The project is driven by the following hypothesis: A computer-based system, enabling 3D MDCT-based procedure planning and follow-on image-guided bronchoscopy, can improve current procedures for the staging, diagnosis, and treatment of lung cancer. The specific aims are as follows. Aim 1: Devise automated methods for MDCT-based procedure planning and image-guided bronchoscopy, thereby enabling more effective biopsy planning and subsequent bronchoscopic biopsy. Aim 2: Prototype a workstation for the interactive planning and guidance of bronchoscopy, thereby providing the physician with a user-friendly system for image-guided bronchoscopy. Aim 3: Perform human studies to establish system functionality and to compare the system to standard practice.These studies, which focus on the bronchoscopic biopsy of suspect mediastinal lymph nodes and peripheral nodules, give a preliminary clinical evaluation and motivate later Phase-Ill and FDA 510K tests. Since the current techniques for diagnosing and staging lung cancer are unsatisfactory, it is critical that accurate tools become available for assessing lung cancer. Further, the impact of therapy and treatment remains largely unchanged over the last twenty years. The image-guided methods featured by the proposed system could make possible the accurate delivery of agents directly into the lung tumor nodule or into involved lymph nodes. With the Virtual Navigator, bronchoscopies can be planned better, more difficult sites can be biopsied, and fewer unsuccessful biopsies will be done. These benefits reduce the need for follow-up procedures, reducing cost and gaining time toward successful treatment, or, stated differently, improve the early diagnosis, staging, and treatment of lung cancer.
该第二阶段 SBIR 项目是为了响应 PAR-01-102“体内成像新技术的开发”。扩展我们第一阶段的可行性工作,我们建议构建和验证一个完整的工作站 - 虚拟导航器 - 用于基于 3D MDCT 的支气管镜活检规划和指导。肺癌是西方国家最常见的癌症死亡原因,目前5年生存率低于15%。尽管继续 随着技术的进步,1979 年至 1997 年间,肺癌死亡率实际上增加了 11%。诊断和分期肺癌的最先进程序包括三维 (3D) 多探测器计算机断层扫描 (MDCT) 扫描,然后进行支气管镜活检。不幸的是,很大比例的活检手术不成功,因为:(1) 缺乏手术规划工具,(2) 难以看到活检部位 支气管镜检查期间,(3) 医生技术水平差异很大。该项目由以下假设驱动:基于计算机的系统能够实现基于 3D MDCT 的手术规划和后续图像引导支气管镜检查,可以改进当前肺癌分期、诊断和治疗的手术。具体目标如下。目标 1:为基于 MDCT 的手术计划和图像引导支气管镜检查设计自动化方法,从而实现更有效的活检计划和随后的支气管镜活检。目标 2: 原型用于支气管镜检查的交互式规划和指导的工作站,从而为医生提供用户友好的图像引导支气管镜检查系统。目标 3:进行人体研究以建立系统功能并将系统与标准实践进行比较。这些研究重点关注可疑纵隔淋巴结和周围结节的支气管镜活检,提供初步的临床评估并激发后续的 III 期和 FDA 510K 测试。由于目前诊断和分期肺癌的技术并不令人满意,因此提供准确的工具来评估肺癌至关重要。此外,治疗和治疗的影响在过去二十年中基本保持不变。该系统所采用的图像引导方法可以使 准确地将药剂直接输送到肺部肿瘤结节或相关淋巴结中。借助虚拟导航器,可以更好地计划支气管镜检查,可以对更困难的部位进行活检,并且可以减少不成功的活检。这些好处减少了后续手术的需要,降低了成本并为成功治疗赢得了时间,或者换句话说,改善了肺癌的早期诊断、分期和治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William Evan Higgins其他文献

William Evan Higgins的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William Evan Higgins', 18)}}的其他基金

Multimodal Image-Guided Intervention System for Lung-Cancer Diagnosis and Staging
用于肺癌诊断和分期的多模态图像引导干预系统
  • 批准号:
    8433224
  • 财政年份:
    2010
  • 资助金额:
    $ 47.32万
  • 项目类别:
Multimodal Image-Guided Intervention System for Lung-Cancer Diagnosis and Staging
用于肺癌诊断和分期的多模态图像引导干预系统
  • 批准号:
    8206807
  • 财政年份:
    2010
  • 资助金额:
    $ 47.32万
  • 项目类别:
Multimodal Image-Guided Intervention System for Lung-Cancer Diagnosis and Staging
用于肺癌诊断和分期的多模态图像引导干预系统
  • 批准号:
    8607839
  • 财政年份:
    2010
  • 资助金额:
    $ 47.32万
  • 项目类别:
Multimodal Image-Guided Intervention System for Lung-Cancer Diagnosis and Staging
用于肺癌诊断和分期的多模态图像引导干预系统
  • 批准号:
    10321636
  • 财政年份:
    2010
  • 资助金额:
    $ 47.32万
  • 项目类别:
Multimodal Image-Guided Intervention System for Lung-Cancer Diagnosis and Staging
用于肺癌诊断和分期的多模态图像引导干预系统
  • 批准号:
    8133730
  • 财政年份:
    2010
  • 资助金额:
    $ 47.32万
  • 项目类别:
Virtual-Endoscopic Reporter for Lung-Cancer Assessment
用于肺癌评估的虚拟内窥镜记者
  • 批准号:
    6337149
  • 财政年份:
    2001
  • 资助金额:
    $ 47.32万
  • 项目类别:
CT-Bronchoscopy Workstation for Lung-Cancer Assessment
用于肺癌评估的 CT 支气管镜工作站
  • 批准号:
    7007678
  • 财政年份:
    2001
  • 资助金额:
    $ 47.32万
  • 项目类别:
CT-Bronchoscopy Workstation for Lung-Cancer Assessment
用于肺癌评估的 CT 支气管镜工作站
  • 批准号:
    6685417
  • 财政年份:
    2001
  • 资助金额:
    $ 47.32万
  • 项目类别:
Synergistic CT-Bronchoscopy for Lung-Cancer Assessment
协同 CT 支气管镜检查用于肺癌评估
  • 批准号:
    6614189
  • 财政年份:
    1997
  • 资助金额:
    $ 47.32万
  • 项目类别:
Synergistic CT-Bronchoscopy for Lung-Cancer Assessment
协同 CT 支气管镜检查用于肺癌评估
  • 批准号:
    7238589
  • 财政年份:
    1997
  • 资助金额:
    $ 47.32万
  • 项目类别:

相似海外基金

Multidimensional phenotype classification in grade 3 BPD
3 级 BPD 的多维表型分类
  • 批准号:
    10632887
  • 财政年份:
    2023
  • 资助金额:
    $ 47.32万
  • 项目类别:
Ancillary SOURCE Study: Characterization of Small Airway Basal Cell Biology in Early COPD
辅助来源研究:早期 COPD 中小气道基底细胞生物学的特征
  • 批准号:
    10736644
  • 财政年份:
    2023
  • 资助金额:
    $ 47.32万
  • 项目类别:
A multicenter study in bronchoscopy combining Stimulated Raman Histology with Artificial intelligence for rapid lung cancer detection - The ON-SITE study
支气管镜检查结合受激拉曼组织学与人工智能快速检测肺癌的多中心研究 - ON-SITE 研究
  • 批准号:
    10698382
  • 财政年份:
    2023
  • 资助金额:
    $ 47.32万
  • 项目类别:
Extending Reach, Accuracy, and Therapeutic Capabilities: A Soft Robot for Peripheral Early-Stage Lung Cancer
扩大范围、准确性和治疗能力:用于周围早期肺癌的软机器人
  • 批准号:
    10637462
  • 财政年份:
    2023
  • 资助金额:
    $ 47.32万
  • 项目类别:
Integrating imaging and biopsy-derived molecular markers for the pre-surgical detection of indolent and aggressive early stage lung adenocarcinoma
整合成像和活检衍生的分子标记物,用于惰性和侵袭性早期肺腺癌的术前检测
  • 批准号:
    10737330
  • 财政年份:
    2023
  • 资助金额:
    $ 47.32万
  • 项目类别:
An Alternative Pathobiology underlying Severe Asthma
严重哮喘的替代病理学
  • 批准号:
    10736884
  • 财政年份:
    2023
  • 资助金额:
    $ 47.32万
  • 项目类别:
Investigating the role of altered lung microbiome in fueling Th17 mediated airway inflammation in COPD among HIV-infected individual
研究肺部微生物组改变在 HIV 感染者 COPD 中促进 Th17 介导的气道炎症的作用
  • 批准号:
    10791969
  • 财政年份:
    2023
  • 资助金额:
    $ 47.32万
  • 项目类别:
Gender and Asthma
性别与哮喘
  • 批准号:
    10583660
  • 财政年份:
    2023
  • 资助金额:
    $ 47.32万
  • 项目类别:
Trained Immunity in the Airway Mucosa Differentiates Asthma from Allergy Alone
气道粘膜经过训练的免疫力可将哮喘与单纯过敏区分开来
  • 批准号:
    10673238
  • 财政年份:
    2023
  • 资助金额:
    $ 47.32万
  • 项目类别:
Determinants of Convalescent and Vaccine-induced Mucosal Specific Immunity to SARS-CoV-2 and Variants of Concern in Children with Asthma
哮喘儿童恢复期和疫苗诱导的 SARS-CoV-2 粘膜特异性免疫以及值得关注的变体的决定因素
  • 批准号:
    10638521
  • 财政年份:
    2023
  • 资助金额:
    $ 47.32万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了